Boehringer Ingelheim's pololike kinase inhibitor volasertib won breakthrough-therapy designation from the FDA as a potential treatment for acute myeloid leukemia. The approval was based on data from a midstage trial that showed volasertib, in combination with low-dose cytarabine, improved overall and event-free survival compared with cytarabine alone.
Boehringer's leukemia candidate wins breakthrough status from FDA
SmartBrief Job Listings for Health Care
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|Catheter Engineer Manager||
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|
|Neurovascular Intervention Product Sales Rep, North East||
|Multiple Locations, SL_Multiple Locations|
|Senior Manager, Compliance||
|Director, Office of Device Evaluation||
FDA, Center for Devices and Radiological Health
|Silver Spring, MD|